The influence of iron on chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 13, Issue 3, 1998, Pages 330-333

  Burt, Michael J ^a   Cooksley, W Graham ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Royal Brisbane and Womens Hospital Research Foundation   (Australia)

Author keywords

Hepatitis C; Interferon; Iron; Venesection

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; IRON; VIRUS RNA;

HEPATITIS C; HUMAN; LIVER LEVEL; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

EID: 0031895097     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.1998.01549.x     Document Type: Review

References (42)

1. Davis GL, Baiart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N. Engl. J. Med. 1989; 321: 1501-6.
2. Saracco G, Rizzetto M. The long-term efficacy of interferon alfa in chronic hepatitis C patients: A critical review. J. Gastroenterol. Hepatol. 1995; 10: 668-73.
3. Smith BC, Strasser SI, Desmond PV. Current perspectives in hepatitis C. Aust. NZ J. Med. 1995; 25: 350-7.
4. Causse X, Godinot H, Chevallier M et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497-502.
5. Lin R, Grierson J, Schoeman MN et al. Can the response to interferon treatment be predicted in patients with chronic active hepatitis C? Aust. NZ J. Med. 1991; 21: 387-92.
6. Pérez P, Pravia R, Linares A et al. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C. Gut 1993; Suppl: S139-40.
7. Lau JYN, Davis GL, Kniffen J et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993; 341: 1501-4.
8. Tsubota A, Chayama K, Arase Y et al. Factors useful in predicting the response to interferon therapy in chronic hepatitis C. J. Gastroenterol. Hepatol. 1993; 8: 535-9.
9. Mita E, Hayashi N, Hagiwara H et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig. Dis. Sci. 1994; 39: 977-82.
10. Pagliaro L, Craxi A, Cammaá C et al. Interferon-α for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994; 19: 820-8.
11. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J. Hepatol. 1994; 21: 1-3.
12. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon α therapy is influenced by the iron content of the liver. J. Hepatol. 1994; 20: 410-15.
13. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-9.
14. Van Thiel DH, Gavaler JS, Wright HI, Friedlander L. Responses to α interferon (IFN) therapy are influenced by the iron content of the liver. Gastroenterology 1992; 102: A904.
15. Piperno A, D'Alba R, Roffi L, Fargion S, Mancia G, Fiorelli G. Relation between α-interferon response and liver iron stores in chronic hepatitis C. Hepatology 1993; 18: 250A.
16. D'Alba R, Sampietro M, Fargion S et al. Iron stores and virus genotypes in chronic hepatitis C: Relation with α-interferon response. Hepalology 1995; 22: 180A.
17. Swanson NR, Prins A, Lareu RR et al. The role of iron indices in predicting response to interferon in cases of CHC with known genotype. Hepatology 1995; 22: 180A.
18. Fargion S, Carazzone A, Molteni V et al. Iron and response to interferon-α in chronic hepatitis C. Hepatology 1995; 22: 415A.
19. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am. J. Clin. Pathol. 1995; 103: 419-24.
20. Castera L, Fourré C, Dussaix E et al. Serum ferritin (SF) levels, HCV viremia and long-term response to interferon alfa therapy in patients with chronic hepatitis C. Hepatology 1995; 22: 181A.
21. Cartabellotta A, Giannitrapani L, Fulco M et al. Response to α-IFN therapy in chronic hepatitis C virus infection, without cirrhosis, is influenced by extrahepatic iron overload. Hepatology 1995; 22: 399A.
22. Prieto J, Barry M, Sherlock S. Serum ferritin in patients with iron overload and with acute and chronic liver diseases Gastroenterology 1975; 68: 525-33.
23. Leggett BA, Brown NN, Bryant SJ, Duplock L, Powell LW, Halliday JW. Factors affecting the concentrations of ferritin in serum in a healthy Australian population. Clin. Chem. 1990; 36: 1350-5.
24. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-13.
25. Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976; 48: 449-55.
26. Serfaty L, Nousbaum JB, Elghouzzi MH, Giral P, Legendre C, Poupon R. Prevalence, severity, and risk factors of liver disease in blood donors positive in a second-generation anti-hepatitis C virus screening test. Hepatology 1995; 21: 725-9.
27. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986; 6: 24-9.
28. Swanson NR, Jeffrey GP, Reed WD. Influence of HCV genotype on α-interferon response in patients with chronic hepatitis C (CHC). J. Gastroenterol. Hepatol. 1994; 9: A91.
29. Marcellin P, Pouteau M, Martinot-Peignoux M et al. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156-65.
30. Britton RS, Ferrali M, Magiera CJ, Recknagel RO, Bacon BR. Increased prooxidant action of hepatic cytosolic low-molecular-weight iron in experimental iron overload. Hepatology 1990; 11: 1038-43.
31. Bacon BR, Britten RS. The pathology of hepatic iron overload: a free radical-mediated process? Hepatology 1990; 11: 127-37.
32. Brock JH. Iron in infection, immunity, inflammation and neoplasia. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron metabolism in health and disease. London: WB Saunders, 1994; 353-89.
33. Good MF, Powell LW, Halliday JW. Iron status and cellular immune competence. Blood Rev. 1988; 2: 43-9.
34. Finter NB, Chapman S, Dowd P et al. The use of interferon-α in viral infections. Drugs 1991; 42: 749-65.
35. Caraceni P, Fagiuoli S, Van Thiel DH. Iron reduction therapy: simply camouflage, or a real weapon? Am. J. Gastroenterol 1994; 89: 970-3.
36. Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM. Beneficial effects of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-α. Hepatology 1993; 18: 150A.
37. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 1994; 89: 986-8.
38. Yano M, Kakumu S, Hayashi H, Takikawa T, Nishimura N. Phlebotomy followed by α-interferon therapy in patients with chronic hepatitis C. Hepatology 1995; 22: 199A.
39. Nan S-H, Fong T-L, Valinluck B, Adkins RH, Redecker AG. Randomized controlled trial of the effect of iron depletion on aminotransferase levels, HCV RNA and response to interferon therapy in patients with chronic hepatitis C virus. Hepatology 1995; 22: 180A.
40. Halliwell B. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br. J. Exp. Pathol. 1989; 70: 737-57.
41. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995; 22: 449-56.
42. Di Bisceglie AM, Bonkovsky H, Krawitt E et al. Iron reduction therapy in chronic hepatitis C. Hepatology 1997; 26: 214A.